BioVentures Investors invests in new commercial technology in the healthcare sector with a focus on medical devices, diagnostics and similar new commercial technology, collectively known as Medtech. We currently have more than $133 million under management in three funds, all focused on the commercial development of innovative healthcare technology.
Why We Invest in Medtech
A confluence of advances in technology and ongoing trends in the market is creating a wealth of opportunities in Medtech innovations, particularly innovations that improve the efficiency of delivering healthcare benefits (i.e. products that are effective and lower overall costs).
Medtech is currently in a period of active innovation and expansion. Fueling this wave of innovation is:
- Convergence, the unification of advanced engineering and biomedical technology with clinical research. This union of engineers, biochemists and other bench scientists with clinical researchers and practitioners is producing new, more effective methods of treating and detecting disease in areas such as drug delivery, percutaneous surgery, advanced diagnostic systems, patient monitoring and healthcare services. Historically, Medtech products have been developed through an iterative process between physicians and manufacturers: physicians state a need, manufacturers develop technology to answer the need. Convergence disrupts this incremental cycle with dynamic changes in methodology and practice for the detection and treatment of disease.
- Advances in genomics that are driving, more patient-tailored, personalized medicine approaches to treating disease. New tools and diagnostic technology are fundamental to this approach.
Highly Experienced Team
BVI has an experienced team that has had lengthy relationships as venture investors, as collaborators and as industry executives. The founders of BioVentures Investors, Peter Feinstein and Marc Goldberg, have worked closely on various healthcare enterprises since 1984. Walter Gilbert, Ph.D., a Nobel Laureate and a Founder of Biogen, has been active in BVI since its inception. Jeff Barnes, who joined BVI in January 2010, has been a co-investor in three BVI portfolio companies while a Partner at Oxford Bioscience Partners. [link to investment team]
Location in World Center of Life Science Research
Massachusetts, with approximately 400 Medtech companies and a unique concentration of universities, teaching hospitals and research institutions is one of the top three centers of life science technology in the U.S . Five of the top eight and seven of the top 16 NIH-funded medical research centers in the U.S. are located in Massachusetts. BVI’s location in the Boston area and its team’s longstanding ties to and participation in the Massachusetts life science cluster provide significant opportunities to access deal flow and talent in the region.
BioVentures Investors Partners